Pregnancy and Childbirth
Conditions
Interventions
Intravenous tranexamic acid
Placebo or Water for injection group
Sponsors
Dr. Oluniyi E. OYEDEJI
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: • Pregnant women aged =18 years scheduled for caesarean section (both emergency and elective) who consent to participate in the study.
Exclusion criteria
Exclusion criteria: • Patients who do not give consent. • Patients with known allergy to tranexamic acid (TXA). • Patients with antepartum haemorrhage, Previous caesarean section, Multiple pregnancy, Polyhydramnios, bleeding disorders, medical disorders like Diabetes Mellitus, Sickle cell disease, Retroviral Disease. • Patients with major hepatic, major cardiac, major renal, major respiratory disorders in pregnancy were excluded. • Pregnant women who required prophylaxis and/or treatment for deep vein thrombosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To determine the quantity of blood loss following administration of TXA 2.To determine the quantity of blood loss following administration of Placebo 3.To determine the difference in the quantity of blood loss at caesarean section in patients administered with pre-operative TXA and Placebo | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine maternal complications following pre-operative intravenous tranexamic acid To determine the incidence of primary postpartum haemorrhage To determine the incidence of Anaemia in the study population To determine the percentage of those who needed further intervention following administration of the drug. To determine the neonatal complications following administration of the drug. To compare APGAR Score at 1 and 5 minutes of neonate of mothers who received pre-operative TXA and Placebo. | — |
Countries
Nigeria
Contacts
Public ContactADEWALE ADEYEMI
MEDICAL DOCTOR SENIOR LECTURER
Outcome results
None listed